







INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) WO 97/21687 (51) International Patent Classification 6: (11) International Publication Number: A1 C07D 239/36 19 June 1997 (19.06.97) (43) International Publication Date: (81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, PCT/US96/19651 (21) International Application Number: ČA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, (22) International Filing Date: 12 December 1996 (12.12.96) PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, (30) Priority Data: 14 December 1995 (14.12.95) US 60/008,641 LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, 28 August 1996 (28.08.96) GB 9617968.4 CM, GA, GN, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ Published With international search report. 07065 (US). Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of (72) Inventors; and amendments. (75) Inventors/Applicants (for US only): HU, Essa, H. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). SI-DLER, Daniel, R. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). DOLLING, UIF, H. [DE/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PATANE, Michael, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (54) Title: PROCESS FOR MAKING DIHYDROPYRIMIDINONES (57) Abstract The present invention provides a process for forming 5-(alkyl or alkoxy)carbonyl-6-alkyl-4-(aryl or alkyl)-3,4-2(1H)dihydropyrimidinones by combining a β-keto ester or diketone, an aldehyde and urea in the presence of a boron reagent, a metal salt (e.g., Cu2O) and a catalyst (e.g., acid). The reaction is typically run in one pot in a solvent to afford dihydropyrimidinones in higher yields and with easier work up than previously known methods.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Amenia	СВ	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazi)	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CC	Congo	KR	Republic of Korea	SG	Singapore
СН	Switzerland	KZ	Kazakhsian	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal .
CN	China	1.R	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ.	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

10

20

25

30



- 1 -

TITLE OF INVENTION PROCESS FOR MAKING DIHYDROPYRIMIDINONES

FIELD OF THE INVENTION

This application is related to U.S. Serial No. 60/008,641, filed as a provisional application on December 14, 1995, the contents of which are hereby incorporated by reference.

The present invention provides a process for forming 5-(alkyl or alkoxy)carbonyl-6-alkyl-4-(aryl or alkyl)-3, 4-2(1H)dihydropyrimidinones by combining a β-keto ester or diketone, an aldehyde and urea. More particularly, the reaction is run in one pot in the presence of a boron reagent, a metal salt and a catalyst to afford yields much higher than from currently accepted methods.

15 BACKGROUND OF THE INVENTION

Dihydropyrimidinone compounds have been extensively studied as calcium channel blockers useful as antihypertensive agents. [See e.g., K.S. Atwal et al., J. Med. Chem 34, 806 (1991); K.S. Atwal et al., J. Med. Chem 33, 2629 (1990); H. Cho et al., J. Med. Chem 32, 2399 (1989); Baldwin et al., U.S. Patent No. 4,675,321, issued June 23, 1987]. More recently, a number of dihydropyrimidinones have been identified as alpha 1a antagonists useful for the treatment of benign prostatic hyperplasia (BPH). [See PCT International Patent Application publication no. WO 96/14846, published 23 May 1996]

The reaction of numerous aldehydes with urea and a β-keto ester to give a tetrahydropyrimidinone was discovered by [Biginelli, Gazz. Chim. Ital., 23, 360 (1893)]. The Biginelli reaction has been studied, improved upon and a mechanism of formation of tetrahydropyrimidinone proposed. [K. Folkers and T.B. Johnson, J. Am. Chem. Soc., 55, 3784 (1933); J.D. Fissekis, and F. Sweet, J. Am. Chem. Soc., 95, 8741(1973)]. Thus in the past, the synthesis of dihydropyrimidinones was most often effected using β-keto ester, aryl aldehyde and urea following the principles of Folkers' method, i.e., catalytic amount of acid (e.g., HCl, H2SO4) in protic solvents (e.g.,

15

25

MeOH, EtOH, AcOH) and heating to reflux for a few hours. [K. Folkers and T.B. Johnson, <u>supra</u>]

There are, however, several disadvantages associated with using Folkers method. First, most of the yields were either around or below 50%. Second, HPLC assays often indicate that a substantial portion of the β -keto ester and aryl aldehyde starting materials are consumed to form alkylidene side product. Third, in cases where acetic acid is used as the solvent system, large amounts of aqueous bases are needed to work up the reaction and the use of sodium bicarbonate or sodium carbonate solutions result in violent bubbling.

More recently, alternative stepwise methods for making dihydropyrimidinones have been proposed (See e.g., K.S. Atwal and B.C. O'Reilly, Heterocycles, 26 (5), 1185 (1987); H. Cho et al., J. Org. Chem., 50, 4227 (1985)]. However, these methods required several steps and the yields from these methods was still often relatively low.

Thus, a need remains for an improved method for making dihydropyrimidinones having reduced formation of unwanted side products resulting in higher yields and easier work-up.

It is therefore an object of the invention to identify an improved method for making dihydropyrimidinone compounds of formula (I).

It is a further object of the invention to identify an improved method for making aryl-dihydropyrimidinone compounds of formula (III) which are useful as calcium channel blockers or as intermediates which can be further derivatized at the N-3 position (e.g., acylated as described in U.S. Patent No. 4,675,321, or alkoxycarbonylated as described in Cho

PCT/US96/19651

et al., J. Med. Chem 32, 2399 (1989)) to afford calcium channel blocking agents.

It is a further object of the invention to identify an improved method for making dihydropyrimidinone compounds of formulas (I) and (III) resulting in higher yields and easier work up than the previously known methods described above.

SUMMARY OF THE INVENTION

The present invention provides a method of forming a compound of formula I

comprising reacting

$$R^1$$
 R^2
 R^3
 R^9 and R^5
 R^5

in the presence of a boron reagent, a metal salt and a catalyst to form the compound (I)

wherein

15

20

R¹, R⁷ and R⁸ are each independently selected from hydrogen, halogen, halogenated C₁₋₁₀ alkyl, unsubstituted or substituted aryl, or

5 unsubstituted or substituted C₁₋₁₀ alkyl wherein the substituent on the alkyl is selected from C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy or aryl; R² is C₁₋₁₀ alkyl, OR⁶, unsubstituted C₃₋₆ cycloalkyl or mono-, di- or tri-substituted C₃₋₆ cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C₁₋₆ alkyl, halogenated C₁₋₆ alkyl, C₁₋₆ alkoxy or halogenated C₁₋₆ alkoxy; R³ and R⁹ are each independently selected from hydrogen, C₁₋₁₀ alkyl or

each R⁴ is independently selected from hydrogen, halogen, cyano, C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy, nitro, C₁₋₁₀ alkyl or halogenated C₁₋₁₀ alkyl;

- each R⁵ is independently selected from hydrogen or C₁₋₁₀ alkyl; R⁶ is selected from unsubstituted or substituted C₁₋₁₀ alkyl wherein the substituent on the alkyl is selected from C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy or aryl; unsubstituted C₃₋₆ cycloalkyl or mono-, di- or trisubstituted C₃₋₆ cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C₁₋₆ alkyl, halogenated C₁₋₆ alkyl, C₁₋₆ alkoxy or halogenated C₁₋₆ alkoxy; or unsubstituted or substituted aryl; and
- n is an integer from one to five. Preferably, R⁹ is hydrogen; more preferably, R⁷, R⁸ and R⁹ are hydrogen and the compound I has the formula

- 5 -

In one embodiment of the present invention is the method wherein

the metal salt is selected from copper (I) chloride, copper (I) oxide, copper (II) chloride, copper (II) sulfate, copper (II) acetate, nickel (II) bromide or palladium (II) acetate;

the catalyst is selected from acetic acid, trifluoroacetic acid, methanol, sulfuric acid, MsOH, dichloroacetic acid, HBr-PPh3 or NH4OAc;

R1 is selected from hydrogen or C1-8 alkyl;

R² is C₁₋₈ alkyl or OR⁶;

15

R³ is selected from C₁₋₈ alkyl or

each R⁴ is independently selected from hydrogen, halogen, C₁₋₅ alkoxy, nitro, C₁₋₈ alkyl or halogenated C₁₋₈ alkyl;

each R⁵ is independently selected from hydrogen or C₁₋₈ alkyl;

R6 is C1-8 alkyl;

25 R⁷, R⁸ and R⁹ are hydrogen; and

n is an integer from one to three.

In a class of the invention is the method further comprising the step of isolating the compound I

5 In a subclass of the invention is the method comprising reacting

in the presence of a boron reagent, a metal salt and a catalyst to form the compound (II)

10

15

wherein all variables are as defined above (i.e., each of the variables can be defined both as described in the broadest description of the general process and as described in the first embodiment of the present invention). Preferably, R⁹ is hydrogen; more preferably, R⁷, R⁸ and R⁹ are hydrogen and the compound II has the formula

Illustrative of the invention is the method comprising reacting

5 in the presence of a boron reagent, a metal salt and a catalyst to form the compound (III)

wherein all variables are as defined above (i.e., each of the variables can be defined both as described in the broadest description of the general process and as described in the first embodiment of the present invention).

Illustrating the invention is the method wherein the reaction is carried out in one pot.

An illustration of the invention is the method wherein the reaction is run in a solvent selected from an ether, an alcohol, a halogenated hydrocarbon or an acid. Preferably, the solvent is selected

- 8 -

from tetrahydrofuran, methanol, methylene chloride or acetic acid. Most preferably, the solvent is tetrahydrofuran.

Exemplifying the invention is the method wherein the boron reagent is selected from BF3, BF3·2H2O, BF3·Me2S, BF3·HOAc,

BF3·Et2O, BF3·Me2O, BF3·t-BuOMe, BF3·CH3OH or BF3·CH3CH2CH2OH. Preferably, the boron reagent is BF3·Et2O.

15

20

An example of the invention is the method wherein the metal salt is selected from copper (I) chloride, copper (I) oxide, copper (II) chloride, copper (II) sulfate, copper (II) acetate, nickel (II) bromide, palladium (II) acetate, copper bromide or palladium acetoacetate.

Preferably, the metal salt is selected from copper (I) chloride, copper (I) oxide, copper (II) chloride, copper (II) sulfate, copper (II) acetate, nickel (II) bromide or palladium (II) acetate. More preferably, the metal salt is selected from copper (I) oxide, copper (I) chloride, nickel (II) bromide or palladium (II) acetate. Most preferably, the metal salt is copper (I) oxide,

Further illustrating the invention is the method wherein the catalyst is selected from acetic acid, trifluoroacetic acid, methanol, sulfuric acid, MsOH, dichloroacetic acid, HBr·PPh3, NH4OAc, triethylamine, pyridine, cinchonine, quinine or quinidine. Preferably, the catalyst is selected from acetic acid, trifluoroacetic acid, methanol, sulfuric acid, MsOH, dichloroacetic acid, HBr·PPh3 or NH4OAc. More preferably, the catalyst is selected from acetic acid, trifluoroacetic acid or methanol. Most preferably, the catalyst is acetic acid.

Further exemplifying the invention is the method wherein
the metal salt is selected from copper (I) oxide, copper (I) chloride, nickel
(II) bromide or palladium (II) acetate; the catalyst is selected from acetic
acid, trifluoroacetic acid or methanol; and the solvent is selected from
tetrahydrofuran, methanol or methylene chloride. Preferably, the metal
salt is copper (I) oxide, the catalyst is acetic acid and the solvent is
tetrahydrofuran. Most preferably, the metal salt is copper (I) oxide, the
catalyst is acetic acid, the solvent is tetrahydrofuran and the reaction is
carried out in one pot.

More particularly illustrating the invention is the method wherein the reaction is run at a temperature range of about 40°C to 100°C. Preferably, the reaction is run at a temperature of about 65°C.

More specifically exemplifying the invention is the method wherein the reaction is heated for a period of from 1 to 20 hours, preferably, from 6 to 20 hours, most preferably, for about 18 hours.

Another aspect of the invention are the compounds of the formulas (IV) and (V), and salts thereof,

wherein R¹, R⁷ and R⁸ are each independently selected hydrogen, halogen, halogenated C₁₋₁₀ alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted C₁₋₁₀ alkyl wherein the substituent on the alkyl is selected from C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy or aryl; R² is C₁₋₁₀ alkyl, OR⁶, unsubstituted C₃₋₆ cycloalkyl or mono-, di- or tri-substituted C₃₋₆ cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C₁₋₆ alkyl, halogenated C₁₋₆ alkyl, C₁₋₆ alkoxy or halogenated C₁₋₆ alkoxy; R³ and R⁹ are each independently selected from hydrogen, C₁₋₁₀ alkyl or

20

each R⁴ is independently selected from hydrogen, halogen, cyano, C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy, nitro, C₁₋₁₀ alkyl or halogenated C₁₋₁₀ alkyl; each R⁵ is independently selected from hydrogen or C₁₋₁₀ alkyl;

R⁶ is selected from unsubstituted or substituted C₁₋₁₀ alkyl wherein the substituent on the alkyl is selected from C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy or aryl; unsubstituted C₃₋₆ cycloalkyl or mono-, di- or trisubstituted C₃₋₆ cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C₁₋₆ alkyl, halogenated C₁₋₆ alkyl, C₁₋₆ alkoxy or halogenated C₁₋₆ alkoxy; or unsubstituted or substituted aryl; and n is an integer from one to five.

In one particular embodiment of this aspect of the invention,

R 1 is selected from hydrogen or C₁₋₈ alkyl;

R² is selected from C₁₋₈ alkyl or OR⁶, where R⁶ is C₁₋₈ alkyl;

R³ is selected from C₁₋₈ alkyl or

each R⁴ is independently selected from hydrogen, halogen, cyano, C₁₋₅ alkoxy, nitro, C₁₋₈ alkyl or halogenated C₁₋₈ alkyl; each R⁵ is independently selected from hydrogen or C₁₋₈ alkyl; R⁷, R⁸ and R⁹ are hydrogen; and n is an integer of from one to three.

20 <u>DETAILED DESCRIPTION OF THE INVENTION</u>

The instant invention provides a process for preparing dihydropyrimidinones in high yields according to the following reaction scheme

- 11 -

$$R^{1}$$
 R^{8}
 R^{8}
 R^{9}
 R^{8}
 R^{9}
 R^{5}
 R^{5}
 R^{8}
 R^{8}
 R^{9}
 R^{5}
 R^{5

R1, R7 and R8 are each independently selected from hydrogen, halogen, halogenated C1-10 alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted C1-10 alkyl wherein the substituent on the alkyl is selected from C1-6 alkoxy, halogenated C1-6 alkoxy or aryl; R2 is C1-10 alkyl, OR6, unsubstituted C3-6 cycloalkyl or mono-, di- or tri-substituted C3-6 cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy or halogenated C1-6 alkoxy;

R3 and R9 are each independently selected from hydrogen, C1-10 alkyl

10 R³ and R⁹ are each independently selected from hydrogen, C₁₋₁₀ alkyl or

each R⁴ is independently selected from hydrogen, halogen, cyano, C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy, nitro, C₁₋₁₀ alkyl or halogenated C₁₋₁₀ alkyl;

each R^5 is independently selected from hydrogen or C_{1-10} alkyl; R^6 is selected from unsubstituted or substituted C_{1-10} alkyl wherein the substituent on the alkyl is selected from C_{1-6} alkoxy, halogenated

15

C1-6 alkoxy or aryl; unsubstituted C3-6 cycloalkyl or mono-, di- or trisubstituted C3-6 cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy or halogenated C1-6 alkoxy; or unsubstituted or substituted aryl; and

n is an integer from one to five. Preferably, R⁷, R⁸ and R⁹ are hydrogen and the compound I has the formula

$$\begin{array}{c|c}
O & R^3 \\
\hline
N-R^5 \\
O & R^5
\end{array}$$

In a preferred embodiment of the instant invention is the improved process for forming 4-aryl-pyrimidinones of the formula (II) as shown below.

$$R^{1}$$
 R^{2}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{2}
 R^{3}
 R^{4}
 R^{5}
 R^{5}
 R^{7}
 R^{8}
 R^{1}
 R^{2}
 R^{5}
 R^{7}
 R^{1}
 R^{5}
 R^{5}
 R^{5}
 R^{5}
 R^{7}
 R^{1}
 R^{5}
 R^{5}
 R^{5}
 R^{5}
 R^{7}
 R^{5}
 R^{5}
 R^{5}

wherein R^1 , R^2 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 and n are as defined above. Preferably, R^7 , R^8 and R^9 are hydrogen and the compound Π has the formula

In the most preferred embodiment of the instant invention is the improved process for forming 4-aryl-pyrimidinones of the formula (III) as shown below.

5

10

wherein R1, R4, R6 and n are as defined above.

Compounds of formulas (I), (II) and (III) are useful as calcium channel blockers and as alpha 1a antagonists. More specifically, compounds of formula (III) are particularly preferred as calcium channel blockers, or as intermediates which can be further derivatized at the N-3 position (e.g., acylated as described in U.S. Patent No. 4,675,321, or alkoxycarbonylated as described in Cho et al., J. Med. Chem 32, 2399 (1989)) to afford calcium channel blocking agents. Similarly, compounds of formula (III) are particularly preferred as alpha 1a

10

20

25

antagonists, or as intermediates which can be further derivatized at the N-3 position as described in WO 96/14846, published 23 May 1996.

The reaction is run in one pot in a solvent selected from an oxygenated organic solvent (e.g., alcohol, ether), a halogenated hydrocarbon or an acid. Preferably, the solvent is selected from tetrahydrofuran, methanol, methylene chloride or acetic acid. Most preferably, the solvent is tetrahydrofuran.

A wide array of β -keto esters or diketones (A) and substituted-benzaldehydes (B') are commercially available allowing one to make aryl-dihydropyrimidinones having a large variety of substituents for R^1 , R^2 and R^3 . Moreover, in addition to aryl aldehydes, it is also possible to utilize alkyl aldehydes in the instant invention to afford alkyl-pyrimidinones of the formula (IV)

Additionally, N-substituted ureas and O-substituted ureas (e.g., O-methylisourea) can be utilized in place of urea (C") to afford the corresponding N-substituted dihydropyrimidinones. A number of N-substituted ureas are commercially available and/or could be easily prepared by one of ordinary skill in the art.

The ratio of starting materials is preferably 1:1:1.5 of A:B:C; however, varying the ratio (e.g., 2:1:3, 1:1:3 or 2:1:1.5 of A:B:C) also gave higher yields than the prior art methods (e.g., Folkers method).

The reaction of β-keto ester or diketone (A), aldehyde or ketone (B) and urea (C) in one pot with an unprecedented combination of a boron reagent, a metal salt and a catalyst affords 5-(alkyl or alkoxy)carbonyl-6-alkyl-4-(aryl or alkyl)-3, 4-2(1H)-dihydropyrimidinone (I) in higher yields than obtained by known methods. The boron reagent used in the instant invention is BF3 which is

10

15

30

commercially available in a variety of forms, all of which can be used in the method of the instant invention. More specifically, the boron reagent is selected from BF3, BF3·2H2O, BF3·Me2S, BF3·HOAc, BF3·R2O (e.g., BF3·Et2O, BF3·Me2O, BF3·tert-butyl methyl etherate), BF3·ROH (e.g., BF3·CH3OH, BF3·CH3CH2CH2OH). Preferably, the boron reagent is BF3·Et2O.

A variety of metal salts can be utilized in the novel reaction of the present invention. For example, copper (I) chloride, copper (I) oxide, copper (II) chloride, copper (II) sulfate, copper (II) acetate, nickel (II) bromide, palladium (II) acetate, copper bromide or palladium acetoacetate can all be used as the metal salt. Preferably, the metal salt is copper (I) chloride, copper (I) oxide, copper (II) chloride, copper (II) sulfate, copper (II) acetate, nickel (II) bromide or palladium (II) acetate. More preferably, the metal salt is copper (I) oxide, copper (I) chloride, nickel (II) bromide or palladium (II) acetate. Most preferably, the metal salt used in the reaction is copper (I) oxide. Catalytic amounts of the metal salt are preferable to one full equivalent in the instant reaction.

The catalyst used in the instant reaction can be a number of different Bronsted acids or bases or an alcohol. For example, suitable catalysts include, but are not limited to, acetic acid, trifluoroacetic acid, methanol, sulfuric acid, MsOH, dichloroacetic acid, HBr·PPh3, NH4OAc, triethylamine, pyridine, cinchonine, quinine or quinidine. Preferably, the catalyst is selected from acetic acid, trifluoroacetic acid, methanol, sulfuric acid, MsOH, dichloroacetic acid, HBr·PPh3 or NH4OAc. More preferably, the catalyst is selected from acetic acid, trifluoroacetic acid or methanol. Most preferably, acetic acid is used as the catalyst.

The reaction can be run at a temperature range of about 40°C to about 100°C. Preferably, the temperature is about 65°C. The reaction mixture is heated for a period of 1 to 20 hours depending on the starting materials used. Preferably, the reaction mixture is heated for a period of 6 to 20 hours; most preferably, for about 18 hours.

In a particularly preferred embodiment of the instant invention, 1 eq. of β -keto ester (A), 1 eq. of arylaldehyde (B), 1.5 eq.



- 16 -

urea (C) are reacted in the presence of 1.3 eq. BF3·Et2O, 10 mol% Cu2O, and 10 mol % AcOH in THF at 65°C for 18 h to afford the dihydropyrimidinone (I) in high yield.

Abbreviations used in the instant specification are as

5 follows:

25

AcOH or HOAc = acetic acid

DMSO = dimethyl sulfoxide

Et = ethyl

EtOAc = ethyl acetate

EtOH = ethanol eq. = equivalent Me = methyl

MeOH = methanol

15 MsOH = methanesulfonic acid

NH4OAc = ammonium acetate

Ph = phenyl

THF = tetrahydrofuran

The term "alkyl," as used herein, includes both straight and branched chain alkanes of the number of carbon atoms specified (e.g., C1-10 alkyl), or any number within this range (i.e., methyl, ethyl, 1-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).

The term "halogenated alkyl," as used herein, includes both straight and branched chain alkanes of the number of carbon atoms specified (e.g., halogenated C₁₋₁₀ alkyl), or any number within this range, wherein one or more of the hydrogen atoms on the alkyl chain is replaced with a halogen atom (e.g., CF₃).

The term "alkoxy," as used herein, refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., C1-6 alkoxy), or any number within this range (i.e., methoxy, ethoxy, etc.).

The term "halogenated alkoxy," as used herein, includes both straight and branched chain alkoxides of the number of carbon

atoms specified (e.g., halogenated C₁-6 alkoxy), or any number within this range, wherein one or more of the hydrogen atoms is replaced with a halogen atom (e.g., OCF₃).

The term "aryl," as used herein, refers to unsubstituted,

5 mono-, di-, tri- or tetra- or penta-substituted aromatic groups such as
phenyl or naphthyl. Preferably, the aryl group is unsubstituted, mono-,
di- or tri-substituted. Examples of substituents which can be present on
the phenyl or naphthyl group include, but are not limited to, halogen,
C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkyl or

10 halogenated C1-6 alkoxy.

As used herein, the term "halogen" shall include, iodine, bromine, chlorine and fluorine.

The following examples are provided to further define the invention without, however, limiting the invention to the particulars of these examples.

EXAMPLE 1

5-Methoxycarbonyl-6-methyl-4-phenyl-3, 4-dihydropyrimidin-2(1H)-one

20

25

15

To a dry round bottom flask containing methyl acetoacetate (0.2322 g, 2.0 mmol), benzaldehyde (0.2122 g, 2.0 mmol) and urea (0.18 g, 3.0 mmol) in 3.6 ml of dry THF (0.5M) was added AcOH (10mol%), CuCl (10mol%) and 1.3 equivalent of BF3-Et2O (2.6 mmol). The reaction was heated at 65°C for 18 h. The reaction was quenched with one volume equivalent of 10% Na₂CO₃ solution and diluted with EtOAc (one volume equivalent). The organic layer containing the product was

10

- 18 -

turned over to toluene and the title compound was crystallized in 88% yield; mp 204-208°C.

1H NMR (250 MHz, CDCl₃) δ 8.08 (s, 1H), 7.30 (M, 5H), 5.70 (s, 1H), 5.39 (d, 1H), 3.62 (s, 3H), 2.34 (s, 3H).

EXAMPLE 2

4-(3,4-Difluorophenyl)-6-ethyl-5-methoxycarbonyl-3,4-dihydropyrimidin-2(1H)-one


To a dry round bottom flask containing methyl propionylacetate (2.0g, 15.4mmol), 3,4-difluorobenzaldehyde (2.1885g, 15.4mmol), and urea (1.39g, 23.1mmol) in 28 ml of dry THF (0.5M) was added AcOH (10mol%), Cu₂O (10mol%) and 1.3 equivalent of BF₃•OEt₂ (20.0mmol). The reaction was heated at 65°C for 18h. Then, the reaction mixture was quenched with one volume equivalent of 10% Na₂CO₃ and diluted with one volume equivalent of EtOAc. The organic layer containing the product was turned over to toluene and the title compound was crystallized in 90% yield; mp 180-184°C.

NMR ¹H (250 MHz, DMSO-d6) δ 9.31 (s, 1H), 7.80 (s, 1H), 7.40 (m, 1H), 7.20 (m, 1H), 7.06 (m, 1H), 5.14 (d, 1H), 3.54 (s, 3H), 2.65 (m, 2H), 1.11 (t, 3H).

15

20





- 19 -

EXAMPLE 3

5-Methoxycarbonyl-6-methoxymethyl-4-(3,4-difluorophenyl)-3,4-dihydropyrimidin-2(1H)-one

5

10

15

To a dry round bottom flask containing methoxy acetoacetate (2.0 g, 13.7 mmol), 3,4-difluorobenzaldehyde (1.95g, 13.7 mmol) and urea (1.23 g, 20.6 mmol) in 28 ml of dry THF (0.5M) was added AcOH (10mol%), CuCl (10mol%) or Cu(OAc)2 and 1.3 e.g. of BF3-Et2O (2.6 mmol). The reaction was heated at 65°C for up to 18 h. The reaction was quenched with one volume equivalent of 10% Na2CO3 solution and diluted with EtOAc (one volume equivalent). The organic layer containing the product was turned over to toluene and the title compound was crystallized in 90% yield; mp: 116-120°C.

¹H NMR (250 MHz, CDCl₃) δ 7.70 (br s, 1H), 7.06 (m, 3H), 6.91 (br s, 1H), 5.32 (s, 1H), 4.62 (s, 2H), 3.63 (s, 3H), 3.44 (s, 3H).



- 20 -

The compounds shown below in Table 1 can be readily prepared by one of ordinary skill in the art according to the methods described in the above Examples by using readily available starting materials.

5

TABLE I

Chemical Name

Structure

6-ethyl-5-methoxycarbonyl-4-phenyl-3, 4-2(1H)-dihydropyrimidinone

6-ethyl-5-methoxycarbonyl-4-(4-methoxyphenyl)-3, 4-2(1H)-dihydropyrimidinone

- 21 -

TABLE I (cont.)

Chemical Name

Structure

4-(4-chlorophenyl)-6-ethyl-5-methoxy-carbonyl-3, 4-2(1H)-dihydropyrimidinone

6-ethyl-5-methoxycarbonyl-4-(4-nitrophenyl)-3, 4-2 (1H)-dihydropyrimidinone

While the foregoing specification teaches the principles of the present invention, with examples for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.



- 22 -

WHAT IS CLAIMED IS:

1. A method of forming a compound of formula I

5 comprising reacting

$$R^1$$
 R^2
 R^3
 R^4
 R^5
 R^5
 R^5
 R^5
 R^5

in the presence of a boron reagent, a metal salt and a catalyst to form the compound (I)

10 wherein

 R^1 , R^7 and R^8 are each independently selected from hydrogen, halogen, halogenated C_{1-10} alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted C_{1-10} alkyl wherein the substituent on the alkyl is selected from C_{1-6} alkoxy, halogenated C_{1-6} alkoxy or aryl;

R² is C₁₋₁₀ alkyl, OR⁶, unsubstituted C₃₋₆ cycloalkyl or mono-, di- or tri-substituted C₃₋₆ cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C₁₋₆ alkyl, halogenated C₁₋₆ alkyl, C₁₋₆ alkoxy or halogenated C₁₋₆ alkoxy;



- 23 -

R³ and R⁹ are each independently selected from hydrogen, C₁₋₁₀ alkyl or

each R⁴ is independently selected from hydrogen, halogen, cyano,

- 5 C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy, nitro, C₁₋₁₀ alkyl or halogenated C₁₋₁₀ alkyl; each R⁵ is independently selected from hydrogen or C₁₋₁₀ alkyl; R⁶ is selected from unsubstituted or substituted C₁₋₁₀ alkyl wherein the substituent on the alkyl is selected from C₁₋₆ alkoxy, halogenated
- 10 C₁₋₆ alkoxy or aryl; unsubstituted C₃₋₆ cycloalkyl or mono-, di- or trisubstituted C₃₋₆ cycloalkyl wherein the substitutents on the cycloalkyl are independently selected from hydroxy, C₁₋₆ alkyl, halogenated C₁₋₆ alkyl, C₁₋₆ alkoxy or halogenated C₁₋₆ alkoxy; or unsubstituted or substituted aryl; and
- 15 n is an integer from one to five.

2. The method of Claim 1, wherein

the metal salt is selected from copper (I) chloride, copper (I) oxide, 20 copper (II) chloride, copper (II) sulfate, copper (II) acetate, nickel (II) bromide or palladium (II) acetate;

the catalyst is selected from acetic acid, trifluoroacetic acid, methanol, sulfuric acid, MsOH, dichloroacetic acid, HBr-PPh3 or NH4OAc;

25
R is selected from hydrogen or C₁₋₈ alkyl;

R² is C₁₋₈ alkyl or OR⁶;

30 R³ is selected from C₁₋₈ alkyl or

- 24 -

each R⁴ is independently selected from hydrogen, halogen, C₁₋₅ alkoxy, nitro, C₁₋₈ alkyl or halogenated C₁₋₈ alkyl;

5 each R⁵ is independently selected from hydrogen or C₁₋₈ alkyl;

R⁶ is C₁₋₈ alkyl;

R⁷, R⁸ and R⁹ are hydrogen; and

n is an integer from one to three.

3. The method of Claim 1, further comprising the step of isolating the compound I


15

10

4. The method of Claim 3, comprising reacting

$$R^1$$
 R^2
 R^2
 R^3
 R^4
 R^2
 R^3
 R^4
 R^3
 R^4
 R^4

in the presence of a boron reagent, a metal salt and a catalyst to form the compound (II)



5. The method of Claim 4, comprising reacting

in the presence of a boron reagent, a metal salt and a catalyst to form the compound (III)

- 6. The method of Claim 1, wherein the reaction is carried out in one pot.
- 7. The method of Claim 1, wherein the reaction is run in a solvent selected from an ether, an alcohol, a halogenated hydrocarbon or an acid.
- 8. The method of Claim 7, wherein the solvent is selected from tetrahydrofuran, methanol, methylene chloride or acetic acid.

- 9. The method of Claim 8, wherein the solvent is tetrahydrofuran.
- 5 10. The method of Claim 7, wherein the boron reagent is selected from BF3, BF3·2H2O, BF3·Me2S, BF3·HOAc, BF3·Et2O, BF3·Me2O, BF3·t-BuOMe, BF3·CH3OH or BF3·CH3CH2CH2OH.
- 11. The method of Claim 10, wherein the boron reagent is 10 BF3·Et2O.
- 12. The method of Claim 10, wherein the metal salt is selected from copper (I) chloride, copper (I) oxide, copper (II) chloride, copper (II) sulfate, copper (II) acetate, nickel (II) bromide, palladium (II) acetate, copper bromide or palladium acetoacetate.
 - 13. The method of Claim 12, wherein the metal salt is selected from copper (I) oxide, copper (I) chloride, nickel (II) bromide or palladium (II) acetate.
 - 14. The method of Claim 13, wherein the metal salt is copper (I) oxide.
- 15. The method of Claim 12, wherein the catalyst is selected from acetic acid, trifluoroacetic acid, methanol, sulfuric acid, MsOH, dichloroacetic acid, HBr·PPh3, NH4OAc, triethylamine, pyridine, cinchonine, quinine or quinidine.
- 16. The method of Claim 15, wherein the catalyst is selected 30 from acetic acid, trifluoroacetic acid or methanol.
 - 17. The method of Claim 16, wherein the catalyst is acetic acid.


- 18. The method of Claim 11, wherein the metal salt is selected from copper (I) oxide, copper (I) chloride, nickel (II) bromide or palladium (II) acetate; the catalyst is selected from acetic acid, trifluoroacetic acid or methanol; and the solvent is selected from tetrahydrofuran, methanol or methylene chloride.
- 19. The method of Claim 18, wherein the metal salt is copper (I) oxide, the catalyst is acetic acid and the solvent is tetrahydrofuran.

10

25

- 20. The method of Claim 19, wherein the reaction is carried out in one pot.
- 21. The method of Claim 20, wherein the reaction is run at a temperature range of about 40°C to 100°C.
 - 22. The method of Claim 21, wherein the reaction is run at a temperature of about 65°C.
- 20 23. The method of Claim 21, wherein the reaction is heated for a period of from 1 to 20 hours.
 - 24. The method of Claim 23, wherein the reaction is heated for about 18 hours.





International application No. PCT/US96/19651

A. CLAS	SIFICATION OF SUBJECT MATTER			
110.01	CO7D 239/36 544/315, 316, 318			
According to	International Patent Classification (IPC) or to both na	tional classification and IPC		
B. FIEL	DS SEARCHED	1 - 10 - cia		
	cumentation searched (classification system followed b	y classification symbols)		
U.S. : 5	44/315, 316, 318			
Documentati	on searched other than minimum documentation to the e	xtent that such documents are included	in the fields searched	
Electronic d	ata base consulted during the international search (nam	e of data base and, where practicable,	search terms used)	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Calegory*	Citation of document, with indication, where app	ropriate, of the relevant passages	Relevant to claim No.	
A	US 5,459,145 A (SACCOMANO E see column 9.	F AL.) 17 October 1995,	1-24	
A, E	US 5,591,853 A (KIENER ET AL. colum n 1.	1-24		
	·			
<u> </u>				
Furt	her documents are listed in the continuation of Box C.	See patent family annex.		
	pecial categories of cited documents:	"I" hater document published after the in date and not in conflict with the appli	cation but cited to understand the	
_ u	ocument defining the general state of the art which is not considered to be of particular relevance	principle or theory underlying the in "X" document of particular relevance; t		
	artier document published on or after the international filing date	considered novel or cannot be considered the document is taken alone	lered to involve an inventive step	
l c	ocument which may throw doubte on priority claim(a) or which is ted to establish the publication date of another citation or other pocial reason (as specified)	"Y" document of particular relevance; considered to involve an inventi-	the claimed invention cannot be	
.0.	ocument referring to an oral disclosure, use, exhibition or other	combined with one or more other st being obvious to a person skilled in	sch documents, such companion	
.ъ. с	ocumens published prior to the international filing date but later than be priority date claimed	'&' document member of the same pate		
	e actual completion of the international search	Date of mailing of the international s		
13 MAF	ICH 1997	/ 1 1 A	PR 1997	
Name and	mailing address of the ISA/US	Authorized officer		
Rox PCT	ioner of Patents and Trademarks on. D.C. 20231	JOHN M-FORDI SEE A SOLITION JO		
Facsimile	No. (703) 305-3230	Telephone No. (703) 308-1235	Car as the	
Form PCT	/ISA/210 (second sheet)(July 1992)*	•	L'	

Form PCT/ISA/210 (second sheet)(July 1992)*